Ontario Teachers Pension Plan Board Has $930,000 Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Ontario Teachers Pension Plan Board lessened its position in Exelixis, Inc. (NASDAQ:EXEL) by 70.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,823 shares of the biotechnology company’s stock after selling 86,517 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Exelixis were worth $930,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. V Square Quantitative Management LLC acquired a new stake in shares of Exelixis in the 3rd quarter valued at $30,000. Park Place Capital Corp acquired a new stake in shares of Exelixis in the 2nd quarter valued at $45,000. GAMMA Investing LLC boosted its stake in shares of Exelixis by 107.9% in the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares in the last quarter. EntryPoint Capital LLC raised its holdings in shares of Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,746 shares during the last quarter. Finally, Capital Performance Advisors LLP bought a new position in shares of Exelixis in the third quarter valued at about $61,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EXEL. Truist Financial lifted their price target on Exelixis from $33.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. BMO Capital Markets lifted their price target on Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Guggenheim lifted their price target on Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. TD Cowen lifted their price target on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Piper Sandler lifted their price target on Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Exelixis has an average rating of “Moderate Buy” and an average target price of $31.44.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 41,588 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the transaction, the executive vice president now owns 288,665 shares in the company, valued at $9,918,529.40. This trade represents a 12.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Dana Aftab sold 1,162 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 289,736 shares of company stock worth $9,471,510 in the last 90 days. Corporate insiders own 2.85% of the company’s stock.

Exelixis Stock Up 0.7 %

NASDAQ:EXEL opened at $34.65 on Thursday. Exelixis, Inc. has a twelve month low of $19.20 and a twelve month high of $36.60. The business has a 50 day moving average price of $29.55 and a two-hundred day moving average price of $25.41. The company has a market cap of $9.90 billion, a P/E ratio of 22.21, a price-to-earnings-growth ratio of 0.88 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same quarter in the prior year, the business posted $0.10 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. As a group, analysts anticipate that Exelixis, Inc. will post 1.68 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.